The worldwide chronic myelomonocytic leukemia (CMML) treatment market is undergoing a period of steady growth. This development can be attributed to several factors, including the growing incidence of CMML, advancements in therapy, and growing awareness about the disease. The market is characterized by a diverse selection of medicines available, in